LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,240.34
−1.33%Jun 23, 2026, 00:00 UTC
Daniel M. Skovronsky, M.D., Ph.D. was appointed to the Board of Directors of Illumina, Inc. effective June 16, 2026.
Jun 19, 2026, 17:58 UTC
ARK Invest increased its stake in Tesla and Snowflake while reducing its stake in Roku on June 18.
Jun 18, 2026, 19:56 UTC
Eli Lilly has begun eliminating mandated 340B drug discounts to dozens of hospitals that failed to provide comprehensive claims data.
Source:Jun 18, 2026, 09:55 UTC
ARK Invest added $46 million worth of Eli Lilly stock on June 17.
Source:Jun 9, 2026, 22:18 UTC
The FDA approved Eli Lilly's EBGLYSS for a maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis.
Source:Jun 9, 2026, 13:35 UTC
AstraZeneca reported encouraging mid-stage trial results for its experimental weight-loss pill elecoglipron, showing 11.8% weight loss after 36 weeks.
Jun 9, 2026, 08:00 UTC
Convatec and the Lilly Foundation committed approximately $5 million to Partners In Health to improve care for non-communicable diseases and chronic conditions.
Jun 4, 2026, 12:25 UTC
Eli Lilly reduces its planned investment in Germany from €2.3 billion to approximately half that amount.
Jun 2, 2026, 21:43 UTC
Cigna drops coverage of GLP-1 obesity drugs for its own employees effective July 1.
Source:Jun 2, 2026, 17:00 UTC
NewLimit raised $435 million in Series C funding led by Founders Fund, with participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross.
Source:Jun 1, 2026, 22:00 UTC
Eli Lilly warned over 1,000 hospitals that they must submit comprehensive claims data within five days or lose their 340B drug discounts.
Source:May 31, 2026, 12:01 UTC
Eli Lilly announced Phase 3 LIBRETTO-432 clinical trial results for Retevmo (selpercatinib) as adjuvant therapy for early-stage RET fusion-positive lung cancer, showing an 83% reduction in risk of disease recurrence or death.
Source:
← PreviousPage 2